Added to YB: 2026-07-21
Pitch date: 2026-07-17
UNCY [bearish]
Unicycive Therapeutics, Inc.
-6.55%
current return
Author Info
BioEquity Watch is a free, independent publication offering in-depth analysis of biotech and pharmaceutical companies, focused on market-relevant research, IPOs, and drug development pipelines. Sign up for the newsletter.
Company Info
Unicycive Therapeutics, Inc., a clinical-stage biotechnology company, identifies, develops, and commercializes therapies for the treatment of kidney diseases in the United States.
Market Cap
$147.4M
Pitch Price
$5.34
Price Target
1.20 (-78%)
Dividend
N/A
EV/EBITDA
-3.13
P/E
-2.56
EV/Sales
N/A
Sector
Biotechnology
Category
special_situation
If you don't change anything, nothing changes : A look at $UNCY.
UNCY (short): Bearish, PT $1.20 vs $5.00 (-76%). 2nd consecutive CRL 6/30/26 after mgmt resubmitted OLC NDA using same failed contract manufacturer, delaying lead drug 12-18mo. $57M cash won't last; dilutive raise before end-2026. Clinical data solid but no moat (505b2 reformulated generic), no buyout leverage. rNPV at 35% PoS, 10% peak share of $2.5B mkt = $38.4M/32M shares.
Read full article (6 min)